SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF ROMIPLOSTIM, ATHROMBOPOIETIN (TPO) - RECEPTOR AGONIST, IN THROMBOCYTOPENIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN AN EXTENSION STUDY

Bussel James; Tarantino Michael; Geddis Amy; Guerrera Michael; Ikeda Alan; Nie Kun; Franklin Janet; Eisen Melissa

首页> 外文期刊>Pediatric blood & cancer >SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF ROMIPLOSTIM, ATHROMBOPOIETIN (TPO) - RECEPTOR AGONIST, IN THROMBOCYTOPENIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN AN EXTENSION STUDY

【24h】

SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF ROMIPLOSTIM, ATHROMBOPOIETIN (TPO) - RECEPTOR AGONIST, IN THROMBOCYTOPENIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN AN EXTENSION STUDY

机译：免疫性血小板减少症（ITP）的血小板减少性小儿患者长期服用罗密洛司姆，血小板生成素（TPO）-激动剂的安全性和有效性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric blood & cancer》 |2015年第2期|共1页
作者
Bussel James; Tarantino Michael; Geddis Amy; Guerrera Michael; Ikeda Alan; Nie Kun; Franklin Janet; Eisen Melissa;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF ROMIPLOSTIM, ATHROMBOPOIETIN (TPO) - RECEPTOR AGONIST, IN THROMBOCYTOPENIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN AN EXTENSION STUDY [J] . Bussel James, Tarantino Michael, Geddis Amy, Pediatric blood & cancer . 2015,第Suppla2期

机译：免疫性血小板减少症（ITP）的血小板减少性小儿患者长期服用罗密洛司姆，血小板生成素（TPO）-激动剂的安全性和有效性
2. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP) [J] . ShirasugiY., AndoK., MiyazakiK., International journal of hematology . 2012,第6期

机译：一项开放性延伸研究，评估romiplostim在日本血小板减少性免疫性血小板减少性紫癜（ITP）患者中的安全性和疗效长达3.5年
3. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP) [J] . Yukari Shirasugi, Kiyoshi Ando, Koji Miyazaki, International Journal of Hematology . 2012,第6期

机译：一项开放性扩展研究，评估romiplostim在日本血小板减少性免疫性血小板减少性紫癜（ITP）患者中长达3.5年的安全性和有效性
4. Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile [C] . Chia-Hung Tsai, James Bussel, Allison Imahiyerobo, IFAC World Congress . 2014

机译：免疫血小板减少紫癜患者血小板计数控制：最佳的romiplosim剂量曲线
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies [O] . David J. Kuter, Adrian Newland, Beng H. Chong, -1

机译：新诊断或持续性免疫性血小板减少症（ITP）长达1年的成年患者和慢性ITP超过1年的成年患者中的Romiplostim：来自已完成romiplostim研究的综合数据的亚组分析
7. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) [O] . T. B. GERNSHEIMER, J. N. GEORGE, L. M. ALEDORT, 2010

机译：在慢性免疫血小板减少症患者（ITP）患者中长期使用血栓淹没期间出血和血栓形成的评估

SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF ROMIPLOSTIM, ATHROMBOPOIETIN (TPO) - RECEPTOR AGONIST, IN THROMBOCYTOPENIC PEDIATRIC PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) IN AN EXTENSION STUDY

著录项

相似文献

相关主题

期刊订阅